<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00578214</url>
  </required_header>
  <id_info>
    <org_study_id>07-000848</org_study_id>
    <nct_id>NCT00578214</nct_id>
  </id_info>
  <brief_title>Safety and Efficacy of Oral Midazolam for Perioperative Anxiety Relief of Patients Undergoing Mohs Micrographic Surgery</brief_title>
  <official_title>Randomized Controlled and Prospective Studies of Safety and Efficacy of Oral Midazolam for Perioperative Anxiolysis of Patients Undergoing Mohs Micrographic Surgery.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Mayo Clinic</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Mayo Clinic</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Midazolam is an approved sedative medication used for medical procedures. This study was
      being done to document the safety and efficacy of midazolam in improving anxiety, heart rate,
      and blood pressure in patients prior to undergoing Mohs micrographic surgery for the
      treatment of skin cancer (basal cell carcinoma or squamous cell carcinoma). Midazolam may
      make a patient relaxed and sleepy, and lower blood pressure. These effects last for about 2
      hours.

      This study had two parts. In the first part, eligible patients were randomized to either
      receiving one standard dose of midazolam syrup or placebo syrup before their surgery, with
      neither the patient nor the study team knowing which patient received the study drug. In the
      second part, patients who were not eligible to participate in the randomized study or who
      refused to participate in the randomized study were enrolled in a prospective arm where they
      knew they were receiving midazolam syrup. In the prospective arm, the doses were based on the
      patient's weight, and patients were given additional doses of midazolam syrup as necessary to
      control their anxiety.

      The primary hypothesis of this study was that a single dose of oral midazolam syrup to
      patients prior undergoing outpatient Mohs micrographic surgery for skin cancer would result
      in lower anxiety scores at 60 minutes compared to placebo. In addition, the second hypothesis
      of this study was that patients given oral midazolam would have the rate of adverse events
      that was not worse than 25% higher than in the placebo group.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The main objective of this study was to establish the safety and efficacy of midazolam in
      patients with skin cancer undergoing outpatient Mohs micrographic surgery. Patients were
      randomized in a double-blind placebo-controlled study of a single-dose midazolam syrup for
      efficacy in producing safe anxiolysis of short duration. A parallel prospective arm of the
      study involved administration of midazolam in an unblinded fashion. Based on available
      studies of orally administered midazolam, the expectation was that the only observed adverse
      events will be minor and the major adverse event rate for midazolam would be similar to
      placebo. Data was collected on vital signs, anxiety, adverse events, and overall satisfaction
      with the anxiolytic agent.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>March 2007</start_date>
  <completion_date type="Actual">June 2008</completion_date>
  <primary_completion_date type="Actual">April 2008</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Patient Anxiety at Baseline</measure>
    <time_frame>Baseline (prior to drug administration)</time_frame>
    <description>A 10-point visual analog scale (VAS) was used to measure anxiety. The patients marked on the scale their feeling of anxiety. The lowest value possible was 0 (no anxiety) and the highest value possible was 10 (highest possible anxiety).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Patient Anxiety at 60 and 120 Minutes</measure>
    <time_frame>60 and 120 minutes after drug administration</time_frame>
    <description>A 10-point visual analog scale (VAS) was used to measure anxiety. The patients marked on the scale their feeling of anxiety. The lowest value possible was 0 (no anxiety) and the highest value possible was 10 (highest possible anxiety).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Patient Alertness at Baseline</measure>
    <time_frame>Baseline (prior to drug administration)</time_frame>
    <description>A 10-point visual analog scale (VAS) was used to measure alertness. The patients marked on the scale their feeling of alertness. The lowest value possible was 0 (awake) and the highest value possible was 10 (barely awake).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient Alertness at 60 and 120 Minutes</measure>
    <time_frame>60 and 120 minutes after drug administration</time_frame>
    <description>A 10-point visual analog scale (VAS) was used to measure alertness. The patients marked on the scale their feeling of alertness. The lowest value possible was 0 (awake) and the highest value possible was 10 (barely awake).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient Cognitive Function at Baseline and 60 Minutes</measure>
    <time_frame>baseline (prior to drug administration) and 60 minutes after drug administration</time_frame>
    <description>Cognitive function was measured by the Mini-Mental State Examination (MMSE), a brief 30 point questionnaire test. The scores can range from 0 (low cognitive function) to 30 (high cognitive function).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient Cognitive Function at 120 Minutes</measure>
    <time_frame>120 minutes after drug administration</time_frame>
    <description>Cognitive function was measured by the Mini-Mental State Examination (MMSE), a brief 30 point questionnaire test. The scores can range from 0 (low cognitive function) to 30 (high cognitive function).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Blood Pressure at 30 Minutes</measure>
    <time_frame>30 minutes after drug administration</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Heart Rate at 30 Minutes</measure>
    <time_frame>30 minutes after drug administration</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Respiratory Rate at 30 Minutes</measure>
    <time_frame>30 minutes after drug administration</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pulse Oximetry at 30 Minutes</measure>
    <time_frame>30 minutes after drug administration</time_frame>
    <description>Pulse oximetry measures the oxygenation of a patient's hemoglobin. A sensor is placed on the patient's finger. Light at red and infrared wavelengths is passed sequentially through the patient to a photodetector. The changing absorbance at each of the two wavelengths is measured, allowing determination of the absorbance. The color of the blood provides a measure of oxygenation (the percentage of hemoglobin molecules bound with oxygen molecules). A healthy young person will probably have an oxygen saturation of 95-99%.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Blood Pressure at 60 Minutes</measure>
    <time_frame>60 minutes after drug administration</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Heart Rate at 60 Minutes</measure>
    <time_frame>60 minutes after drug administration</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Respiratory Rate at 60 Minutes</measure>
    <time_frame>60 minutes after drug administration</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pulse Oximetry at 60 Minutes</measure>
    <time_frame>60 minutes after drug administration</time_frame>
    <description>Pulse oximetry measures the oxygenation of a patient's hemoglobin. A sensor is placed on the patient's finger. Light at red and infrared wavelengths is passed sequentially through the patient to a photodetector. The changing absorbance at each of the two wavelengths is measured, allowing determination of the absorbance. The color of the blood provides a measure of oxygenation (the percentage of hemoglobin molecules bound with oxygen molecules). A healthy young person will probably have an oxygen saturation of 95-99%.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">75</enrollment>
  <condition>Basal Cell Carcinoma</condition>
  <condition>Squamous Cell Carcinoma</condition>
  <condition>Skin Cancer</condition>
  <condition>Anxiety</condition>
  <arm_group>
    <arm_group_label>Randomized Midazolam</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Single-dose midazolam</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Prospective Midazolam</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Randomized Midazolam</intervention_name>
    <description>Midazolam was prepared in a 2 mg/ml cherry flavored syrup. In the randomized arm, patients received a single-dose administration of 5 ml (10 mg) of the midazolam syrup.</description>
    <arm_group_label>Randomized Midazolam</arm_group_label>
    <other_name>Versed</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>The placebo was prepared as a color- and texture-matched cherry flavored syrup without midazolam.</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Local Anesthesia</intervention_name>
    <description>Lidocaine 1% with 1:100,000 epinephrine</description>
    <arm_group_label>Randomized Midazolam</arm_group_label>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_label>Prospective Midazolam</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Prospective Midazolam</intervention_name>
    <description>Midazolam was prepared in a 2 mg/ml cherry flavored syrup. Dosing in the prospective arm was based on weight (&gt;45 to 77 kg, 10 mg; &gt;77 to 100 kg, 15 mg; greater than or equal to 100 kg, 20 mg). In the prospective arm patients were given additional doses of midazolam as necessary (in 5 mg increments) to achieve and maintain the desired level of anxiolysis.</description>
    <arm_group_label>Prospective Midazolam</arm_group_label>
    <other_name>Versed</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        - 1 or 2 sites of biopsy-confirmed squamous cell or basal cell carcinomas limited to head
        and neck regions

        Inclusion Criteria for Prospective Arm:

          -  Patients wishing to receive oral midazolam in a non-blinded fashion will not be
             excluded based on the size of an individual tumor, total number of tumors, or prior
             history of oral midazolam

          -  No upper weight limitation

        Exclusion Criteria:

          -  Prior history of allergy to midazolam or any of the syrup components

          -  History of hypersensitivity to other benzodiazepines

          -  Congestive heart failure (AHA Class III and IV)

          -  Renal failure requiring hemodialysis

          -  End-stage liver failure

          -  Chronic alcoholism or alcohol intoxication within 24 hours of surgery

          -  Untreated or uncontrolled open angle glaucoma

          -  Uncontrolled hypertension

          -  History of psychoses or affective disorders

          -  Neuromuscular disorders such as myasthenia gravis

          -  Chronic obstructive pulmonary disease

          -  Patients on medications interfering with renal excretion or microsomal metabolism
             unless the last dose was taken greater than or equal to 5 half-lives prior to surgery

          -  Patients weighing less than 100 lb (45 kg)

          -  Pregnant women; women of childbearing potential will be required to take an in-office
             urine pregnancy test.

          -  Breast-feeding mothers must stop breast-feeding for 7 days after taking midazolam to
             take part in this study

        Additional Exclusion Criteria for Randomized Arms:

          -  Patients with a single cancer &gt; 5 cm in the greatest dimension or with more than 2
             cancers

          -  Patients who were previously premedicated with oral midazolam during prior Mohs
             micrographic surgery episodes

          -  Patients weighing more than 220 lb (100 kg)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Clark C Otley, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Mayo Clinic</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Larisa Ravitskiy, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Mayo Clinic</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Mayo Clinic</name>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <zip>55905</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://clinicaltrials.mayo.edu</url>
    <description>Mayo Clinic Clinical Trials</description>
  </link>
  <results_reference>
    <citation>Ravitskiy L, Phillips PK, Roenigk RK, Weaver AL, Killian JM, Hoverson Schott A, Otley CC. The use of oral midazolam for perioperative anxiolysis of healthy patients undergoing Mohs surgery: conclusions from randomized controlled and prospective studies. J Am Acad Dermatol. 2011 Feb;64(2):310-22. doi: 10.1016/j.jaad.2010.02.038.</citation>
    <PMID>21238825</PMID>
  </results_reference>
  <verification_date>February 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 20, 2007</study_first_submitted>
  <study_first_submitted_qc>December 20, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 21, 2007</study_first_posted>
  <results_first_submitted>January 13, 2012</results_first_submitted>
  <results_first_submitted_qc>February 8, 2012</results_first_submitted_qc>
  <results_first_posted type="Estimate">February 9, 2012</results_first_posted>
  <last_update_submitted>February 8, 2012</last_update_submitted>
  <last_update_submitted_qc>February 8, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 9, 2012</last_update_posted>
  <responsible_party>
    <name_title>Larisa Ravitskiy, MD</name_title>
    <organization>Mayo Clinic</organization>
  </responsible_party>
  <keyword>mohs micrographic surgery</keyword>
  <keyword>skin cancer</keyword>
  <keyword>anxiety</keyword>
  <keyword>basal cell carcinoma</keyword>
  <keyword>squamous cell carcinoma</keyword>
  <keyword>midazolam</keyword>
  <keyword>versed</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Carcinoma, Squamous Cell</mesh_term>
    <mesh_term>Anxiety Disorders</mesh_term>
    <mesh_term>Carcinoma, Basal Cell</mesh_term>
    <mesh_term>Skin Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Midazolam</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Patients undergoing outpatient Mohs surgery at the Mayo Clinic in Rochester, MN were included in either the randomized arms (midazolam vs placebo) or in the prospective midazolam arm. The study was performed between March 2007 and June 2008.</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Randomized Midazolam</title>
          <description>Randomized patients receiving single-dose midazolam syrup</description>
        </group>
        <group group_id="P2">
          <title>Placebo</title>
          <description>Randomized patients receiving placebo syrup</description>
        </group>
        <group group_id="P3">
          <title>Prospective Midazolam</title>
          <description>Open-label, dose of Midazolam based on patient's weight, additional doses to control anxiety were possible</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="22"/>
                <participants group_id="P2" count="22"/>
                <participants group_id="P3" count="31"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="22"/>
                <participants group_id="P2" count="22"/>
                <participants group_id="P3" count="31"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Randomized Midazolam</title>
          <description>Randomized patients receiving single-dose midazolam syrup</description>
        </group>
        <group group_id="B2">
          <title>Placebo</title>
          <description>Randomized patients receiving placebo syrup</description>
        </group>
        <group group_id="B3">
          <title>Prospective Midazolam</title>
          <description>Open-label, dose of Midazolam based on patient's weight, additional doses to control anxiety were possible</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="22"/>
            <count group_id="B2" value="22"/>
            <count group_id="B3" value="31"/>
            <count group_id="B4" value="75"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="71.9" spread="11.5"/>
                    <measurement group_id="B2" value="70.1" spread="12.8"/>
                    <measurement group_id="B3" value="62.9" spread="14.1"/>
                    <measurement group_id="B4" value="67.7" spread="13.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                    <measurement group_id="B2" value="10"/>
                    <measurement group_id="B3" value="21"/>
                    <measurement group_id="B4" value="40"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="13"/>
                    <measurement group_id="B2" value="12"/>
                    <measurement group_id="B3" value="10"/>
                    <measurement group_id="B4" value="35"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="22"/>
                    <measurement group_id="B2" value="22"/>
                    <measurement group_id="B3" value="31"/>
                    <measurement group_id="B4" value="75"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Weight at study entry</title>
          <units>kg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="83.1" spread="13.23"/>
                    <measurement group_id="B2" value="80.6" spread="11.82"/>
                    <measurement group_id="B3" value="87.8" spread="20.16"/>
                    <measurement group_id="B4" value="84.3" spread="16.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Prior Mohs Micrographic Surgery</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>No</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="16"/>
                    <measurement group_id="B2" value="17"/>
                    <measurement group_id="B3" value="21"/>
                    <measurement group_id="B4" value="54"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Yes</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="9"/>
                    <measurement group_id="B4" value="18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Unknown</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Type of Non-melanoma Skin Cancer</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Basal Cell Carcinoma</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="13"/>
                    <measurement group_id="B2" value="11"/>
                    <measurement group_id="B3" value="22"/>
                    <measurement group_id="B4" value="46"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Squamous Cell Carcinoma</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                    <measurement group_id="B2" value="10"/>
                    <measurement group_id="B3" value="8"/>
                    <measurement group_id="B4" value="27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Basal Cell and Squamous Cell Carcinomas</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Patient Anxiety at Baseline</title>
        <description>A 10-point visual analog scale (VAS) was used to measure anxiety. The patients marked on the scale their feeling of anxiety. The lowest value possible was 0 (no anxiety) and the highest value possible was 10 (highest possible anxiety).</description>
        <time_frame>Baseline (prior to drug administration)</time_frame>
        <population>The analysis was done on the patients who completed the assessment. One patient in the randomized midazolam arm, 2 patients in the placebo arm, and 1 patient in the prospective midazolam arm did not complete this assessment.</population>
        <group_list>
          <group group_id="O1">
            <title>Randomized Midazolam</title>
            <description>Randomized patients receiving single-dose midazolam syrup</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Randomized patients receiving placebo syrup</description>
          </group>
          <group group_id="O3">
            <title>Prospective Midazolam</title>
            <description>Open-label, dose of Midazolam based on patient's weight, additional doses to control anxiety were possible</description>
          </group>
        </group_list>
        <measure>
          <title>Patient Anxiety at Baseline</title>
          <description>A 10-point visual analog scale (VAS) was used to measure anxiety. The patients marked on the scale their feeling of anxiety. The lowest value possible was 0 (no anxiety) and the highest value possible was 10 (highest possible anxiety).</description>
          <population>The analysis was done on the patients who completed the assessment. One patient in the randomized midazolam arm, 2 patients in the placebo arm, and 1 patient in the prospective midazolam arm did not complete this assessment.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="21"/>
                <count group_id="O2" value="20"/>
                <count group_id="O3" value="30"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.3" spread="1.5"/>
                    <measurement group_id="O2" value="1.4" spread="1.6"/>
                    <measurement group_id="O3" value="3.4" spread="2.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Patient Alertness at Baseline</title>
        <description>A 10-point visual analog scale (VAS) was used to measure alertness. The patients marked on the scale their feeling of alertness. The lowest value possible was 0 (awake) and the highest value possible was 10 (barely awake).</description>
        <time_frame>Baseline (prior to drug administration)</time_frame>
        <population>The analysis was done on the patients who completed the assessment. One patient in the randomized midazolam arm did not complete this assessment.</population>
        <group_list>
          <group group_id="O1">
            <title>Randomized Midazolam</title>
            <description>Randomized patients receiving single-dose midazolam syrup</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Randomized patients receiving placebo syrup</description>
          </group>
          <group group_id="O3">
            <title>Prospective Midazolam</title>
            <description>Open-label, dose of Midazolam based on patient's weight, additional doses to control anxiety were possible</description>
          </group>
        </group_list>
        <measure>
          <title>Patient Alertness at Baseline</title>
          <description>A 10-point visual analog scale (VAS) was used to measure alertness. The patients marked on the scale their feeling of alertness. The lowest value possible was 0 (awake) and the highest value possible was 10 (barely awake).</description>
          <population>The analysis was done on the patients who completed the assessment. One patient in the randomized midazolam arm did not complete this assessment.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="21"/>
                <count group_id="O2" value="22"/>
                <count group_id="O3" value="31"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.2" spread="0.6"/>
                    <measurement group_id="O2" value="0.2" spread="0.7"/>
                    <measurement group_id="O3" value="0.2" spread="0.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Patient Alertness at 60 and 120 Minutes</title>
        <description>A 10-point visual analog scale (VAS) was used to measure alertness. The patients marked on the scale their feeling of alertness. The lowest value possible was 0 (awake) and the highest value possible was 10 (barely awake).</description>
        <time_frame>60 and 120 minutes after drug administration</time_frame>
        <population>The analysis was done on the patients who completed the assessment. One patient in the randomized midazolam arm and 1 patient in the prospective midazolam arm did not complete this assessment.</population>
        <group_list>
          <group group_id="O1">
            <title>Randomized Midazolam</title>
            <description>Randomized patients receiving single-dose midazolam syrup</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Randomized patients receiving placebo syrup</description>
          </group>
          <group group_id="O3">
            <title>Prospective Midazolam</title>
            <description>Open-label, dose of Midazolam based on patient's weight, additional doses to control anxiety were possible</description>
          </group>
        </group_list>
        <measure>
          <title>Patient Alertness at 60 and 120 Minutes</title>
          <description>A 10-point visual analog scale (VAS) was used to measure alertness. The patients marked on the scale their feeling of alertness. The lowest value possible was 0 (awake) and the highest value possible was 10 (barely awake).</description>
          <population>The analysis was done on the patients who completed the assessment. One patient in the randomized midazolam arm and 1 patient in the prospective midazolam arm did not complete this assessment.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="21"/>
                <count group_id="O2" value="22"/>
                <count group_id="O3" value="30"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>60 min patient alertness</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.7" spread="4.0"/>
                    <measurement group_id="O2" value="0.7" spread="1.6"/>
                    <measurement group_id="O3" value="5.1" spread="3.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>120 min patient alertness</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.1" spread="2.9"/>
                    <measurement group_id="O2" value="0.5" spread="1.1"/>
                    <measurement group_id="O3" value="3.4" spread="2.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Patient Anxiety at 60 and 120 Minutes</title>
        <description>A 10-point visual analog scale (VAS) was used to measure anxiety. The patients marked on the scale their feeling of anxiety. The lowest value possible was 0 (no anxiety) and the highest value possible was 10 (highest possible anxiety).</description>
        <time_frame>60 and 120 minutes after drug administration</time_frame>
        <population>The analysis was done on the patients who completed the assessment. One patient in the randomized midazolam arm did not complete this assessment.</population>
        <group_list>
          <group group_id="O1">
            <title>Randomized Midazolam</title>
            <description>Randomized patients receiving single-dose midazolam syrup</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Randomized patients receiving placebo syrup</description>
          </group>
          <group group_id="O3">
            <title>Prospective Midazolam</title>
            <description>Open-label, dose of Midazolam based on patient's weight, additional doses to control anxiety were possible</description>
          </group>
        </group_list>
        <measure>
          <title>Patient Anxiety at 60 and 120 Minutes</title>
          <description>A 10-point visual analog scale (VAS) was used to measure anxiety. The patients marked on the scale their feeling of anxiety. The lowest value possible was 0 (no anxiety) and the highest value possible was 10 (highest possible anxiety).</description>
          <population>The analysis was done on the patients who completed the assessment. One patient in the randomized midazolam arm did not complete this assessment.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="21"/>
                <count group_id="O2" value="22"/>
                <count group_id="O3" value="31"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>60 min patient anxiety</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.1" spread="0.5"/>
                    <measurement group_id="O2" value="0.8" spread="0.9"/>
                    <measurement group_id="O3" value="1.0" spread="1.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>120 min patient anxiety</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.2" spread="0.5"/>
                    <measurement group_id="O2" value="0.4" spread="0.8"/>
                    <measurement group_id="O3" value="0.8" spread="1.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Patient Cognitive Function at Baseline and 60 Minutes</title>
        <description>Cognitive function was measured by the Mini-Mental State Examination (MMSE), a brief 30 point questionnaire test. The scores can range from 0 (low cognitive function) to 30 (high cognitive function).</description>
        <time_frame>baseline (prior to drug administration) and 60 minutes after drug administration</time_frame>
        <population>The analysis was done on the patients who completed the assessment. One patient in the prospective midazolam arm did not complete this assessment.</population>
        <group_list>
          <group group_id="O1">
            <title>Randomized Midazolam</title>
            <description>Randomized patients receiving single-dose midazolam syrup</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Randomized patients receiving placebo syrup</description>
          </group>
          <group group_id="O3">
            <title>Prospective Midazolam</title>
            <description>Open-label, dose of Midazolam based on patient's weight, additional doses to control anxiety were possible</description>
          </group>
        </group_list>
        <measure>
          <title>Patient Cognitive Function at Baseline and 60 Minutes</title>
          <description>Cognitive function was measured by the Mini-Mental State Examination (MMSE), a brief 30 point questionnaire test. The scores can range from 0 (low cognitive function) to 30 (high cognitive function).</description>
          <population>The analysis was done on the patients who completed the assessment. One patient in the prospective midazolam arm did not complete this assessment.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="22"/>
                <count group_id="O2" value="22"/>
                <count group_id="O3" value="30"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline Cognitive Function</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="28.9" spread="1.4"/>
                    <measurement group_id="O2" value="29.3" spread="0.9"/>
                    <measurement group_id="O3" value="29.2" spread="1.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>60 min Cognitive Function</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="22.9" spread="10.6"/>
                    <measurement group_id="O2" value="29.4" spread="0.7"/>
                    <measurement group_id="O3" value="24.3" spread="10.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Patient Cognitive Function at 120 Minutes</title>
        <description>Cognitive function was measured by the Mini-Mental State Examination (MMSE), a brief 30 point questionnaire test. The scores can range from 0 (low cognitive function) to 30 (high cognitive function).</description>
        <time_frame>120 minutes after drug administration</time_frame>
        <population>The analysis was done on the patients who completed the assessment. Two patients in the placebo arm did not complete this assessment.</population>
        <group_list>
          <group group_id="O1">
            <title>Randomized Midazolam</title>
            <description>Randomized patients receiving single-dose midazolam syrup</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Randomized patients receiving placebo syrup</description>
          </group>
          <group group_id="O3">
            <title>Prospective Midazolam</title>
            <description>Open-label, dose of Midazolam based on patient's weight, additional doses to control anxiety were possible</description>
          </group>
        </group_list>
        <measure>
          <title>Patient Cognitive Function at 120 Minutes</title>
          <description>Cognitive function was measured by the Mini-Mental State Examination (MMSE), a brief 30 point questionnaire test. The scores can range from 0 (low cognitive function) to 30 (high cognitive function).</description>
          <population>The analysis was done on the patients who completed the assessment. Two patients in the placebo arm did not complete this assessment.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="22"/>
                <count group_id="O2" value="20"/>
                <count group_id="O3" value="31"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="26.0" spread="8.6"/>
                    <measurement group_id="O2" value="29.2" spread="1.2"/>
                    <measurement group_id="O3" value="27.5" spread="7.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Blood Pressure at 30 Minutes</title>
        <time_frame>30 minutes after drug administration</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Randomized Midazolam</title>
            <description>Randomized patients receiving single-dose midazolam syrup</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Randomized patients receiving placebo syrup</description>
          </group>
          <group group_id="O3">
            <title>Prospective Midazolam</title>
            <description>Open-label, dose of Midazolam based on patient's weight, additional doses to control anxiety were possible</description>
          </group>
        </group_list>
        <measure>
          <title>Blood Pressure at 30 Minutes</title>
          <units>mm Hg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="22"/>
                <count group_id="O2" value="22"/>
                <count group_id="O3" value="31"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>30 min Systolic Blood Pressure</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="121.4" spread="19.50"/>
                    <measurement group_id="O2" value="125.9" spread="12.24"/>
                    <measurement group_id="O3" value="118.5" spread="16.99"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>30 min Diastolic Blood Pressure</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="67.1" spread="12.9"/>
                    <measurement group_id="O2" value="68.4" spread="7.82"/>
                    <measurement group_id="O3" value="63.2" spread="10.58"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Heart Rate at 30 Minutes</title>
        <time_frame>30 minutes after drug administration</time_frame>
        <population>The analysis was done on the patients who completed the assessment. One patient in the placebo arm did not complete this assessment.</population>
        <group_list>
          <group group_id="O1">
            <title>Randomized Midazolam</title>
            <description>Randomized patients receiving single-dose midazolam syrup</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Randomized patients receiving placebo syrup</description>
          </group>
          <group group_id="O3">
            <title>Prospective Midazolam</title>
            <description>Open-label, dose of Midazolam based on patient's weight, additional doses to control anxiety were possible</description>
          </group>
        </group_list>
        <measure>
          <title>Heart Rate at 30 Minutes</title>
          <population>The analysis was done on the patients who completed the assessment. One patient in the placebo arm did not complete this assessment.</population>
          <units>heart beats per minute</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="22"/>
                <count group_id="O2" value="21"/>
                <count group_id="O3" value="31"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="61.7" spread="14.84"/>
                    <measurement group_id="O2" value="64.3" spread="8.16"/>
                    <measurement group_id="O3" value="72.1" spread="12.65"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Respiratory Rate at 30 Minutes</title>
        <time_frame>30 minutes after drug administration</time_frame>
        <population>The analysis was done on the patients who completed the assessment. Three patients in the randomized midazolam arm and 2 patients in the placebo arm did not complete this assessment.</population>
        <group_list>
          <group group_id="O1">
            <title>Randomized Midazolam</title>
            <description>Randomized patients receiving single-dose midazolam syrup</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Randomized patients receiving placebo syrup</description>
          </group>
          <group group_id="O3">
            <title>Prospective Midazolam</title>
            <description>Open-label, dose of Midazolam based on patient's weight, additional doses to control anxiety were possible</description>
          </group>
        </group_list>
        <measure>
          <title>Respiratory Rate at 30 Minutes</title>
          <population>The analysis was done on the patients who completed the assessment. Three patients in the randomized midazolam arm and 2 patients in the placebo arm did not complete this assessment.</population>
          <units>breaths per minute</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="19"/>
                <count group_id="O2" value="20"/>
                <count group_id="O3" value="31"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="19.4" spread="12.26"/>
                    <measurement group_id="O2" value="16.1" spread="2.63"/>
                    <measurement group_id="O3" value="16.2" spread="3.07"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Pulse Oximetry at 30 Minutes</title>
        <description>Pulse oximetry measures the oxygenation of a patient's hemoglobin. A sensor is placed on the patients finger. Light at red and infrared wavelengths is passed sequentially through the patient to a photodetector. The changing absorbance at each of the two wavelengths is measured, allowing determination of the absorbance. The color of the blood provides a measure of oxygenation (the percentage of hemoglobin molecules bound with oxygen molecules). A healthy young person will probably have an oxygen saturation of 95-99%.</description>
        <time_frame>30 minutes after drug administration</time_frame>
        <population>The analysis was done on the patients who completed the assessment. Three patients in the randomized midazolam arm and 2 patients in the placebo arm did not complete this assessment.</population>
        <group_list>
          <group group_id="O1">
            <title>Randomized Midazolam</title>
            <description>Randomized patients receiving single-dose midazolam syrup</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Randomized patients receiving placebo syrup</description>
          </group>
          <group group_id="O3">
            <title>Prospective Midazolam</title>
            <description>Open-label, dose of Midazolam based on patient's weight, additional doses to control anxiety were possible</description>
          </group>
        </group_list>
        <measure>
          <title>Pulse Oximetry at 30 Minutes</title>
          <description>Pulse oximetry measures the oxygenation of a patient's hemoglobin. A sensor is placed on the patients finger. Light at red and infrared wavelengths is passed sequentially through the patient to a photodetector. The changing absorbance at each of the two wavelengths is measured, allowing determination of the absorbance. The color of the blood provides a measure of oxygenation (the percentage of hemoglobin molecules bound with oxygen molecules). A healthy young person will probably have an oxygen saturation of 95-99%.</description>
          <population>The analysis was done on the patients who completed the assessment. Three patients in the randomized midazolam arm and 2 patients in the placebo arm did not complete this assessment.</population>
          <units>percentage of oxygenation</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="19"/>
                <count group_id="O2" value="20"/>
                <count group_id="O3" value="31"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="94.5" spread="2.18"/>
                    <measurement group_id="O2" value="95.6" spread="2.11"/>
                    <measurement group_id="O3" value="95.6" spread="2.56"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Blood Pressure at 60 Minutes</title>
        <time_frame>60 minutes after drug administration</time_frame>
        <population>The analysis was done on the patients who completed the assessment. Three patients in the randomized midazolam arm and 2 patients in the placebo arm did not complete this assessment.</population>
        <group_list>
          <group group_id="O1">
            <title>Randomized Midazolam</title>
            <description>Randomized patients receiving single-dose midazolam syrup</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Randomized patients receiving placebo syrup</description>
          </group>
          <group group_id="O3">
            <title>Prospective Midazolam</title>
            <description>Open-label, dose of Midazolam based on patient's weight, additional doses to control anxiety were possible</description>
          </group>
        </group_list>
        <measure>
          <title>Blood Pressure at 60 Minutes</title>
          <population>The analysis was done on the patients who completed the assessment. Three patients in the randomized midazolam arm and 2 patients in the placebo arm did not complete this assessment.</population>
          <units>mm Hg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="19"/>
                <count group_id="O2" value="20"/>
                <count group_id="O3" value="31"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>60 min systolic blood pressure</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="120.1" spread="18.10"/>
                    <measurement group_id="O2" value="131.9" spread="14.59"/>
                    <measurement group_id="O3" value="113.5" spread="15.61"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>60 min diastolic blood pressure</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="65.3" spread="9.17"/>
                    <measurement group_id="O2" value="69.5" spread="8.69"/>
                    <measurement group_id="O3" value="61.5" spread="10.04"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Heart Rate at 60 Minutes</title>
        <time_frame>60 minutes after drug administration</time_frame>
        <population>The analysis was done on the patients who completed the assessment. Three patients in the randomized midazolam arm and 2 patients in the placebo arm did not complete this assessment.</population>
        <group_list>
          <group group_id="O1">
            <title>Randomized Midazolam</title>
            <description>Randomized patients receiving single-dose midazolam syrup</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Randomized patients receiving placebo syrup</description>
          </group>
          <group group_id="O3">
            <title>Prospective Midazolam</title>
            <description>Open-label, dose of Midazolam based on patient's weight, additional doses to control anxiety were possible</description>
          </group>
        </group_list>
        <measure>
          <title>Heart Rate at 60 Minutes</title>
          <population>The analysis was done on the patients who completed the assessment. Three patients in the randomized midazolam arm and 2 patients in the placebo arm did not complete this assessment.</population>
          <units>heart beats per minute</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="19"/>
                <count group_id="O2" value="20"/>
                <count group_id="O3" value="31"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="60.3" spread="13.94"/>
                    <measurement group_id="O2" value="61.4" spread="7.45"/>
                    <measurement group_id="O3" value="69.6" spread="10.75"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Respiratory Rate at 60 Minutes</title>
        <time_frame>60 minutes after drug administration</time_frame>
        <population>The analysis was done on the patients who completed the assessment. Three patients in the randomized midazolam arm and 3 patients in the placebo arm did not complete this assessment.</population>
        <group_list>
          <group group_id="O1">
            <title>Randomized Midazolam</title>
            <description>Randomized patients receiving single-dose midazolam syrup</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Randomized patients receiving placebo syrup</description>
          </group>
          <group group_id="O3">
            <title>Prospective Midazolam</title>
            <description>Open-label, dose of Midazolam based on patient's weight, additional doses to control anxiety were possible</description>
          </group>
        </group_list>
        <measure>
          <title>Respiratory Rate at 60 Minutes</title>
          <population>The analysis was done on the patients who completed the assessment. Three patients in the randomized midazolam arm and 3 patients in the placebo arm did not complete this assessment.</population>
          <units>breaths per minute</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="19"/>
                <count group_id="O2" value="19"/>
                <count group_id="O3" value="31"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20.6" spread="12.33"/>
                    <measurement group_id="O2" value="16.3" spread="2.43"/>
                    <measurement group_id="O3" value="16.8" spread="2.69"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Pulse Oximetry at 60 Minutes</title>
        <description>Pulse oximetry measures the oxygenation of a patient's hemoglobin. A sensor is placed on the patients finger. Light at red and infrared wavelengths is passed sequentially through the patient to a photodetector. The changing absorbance at each of the two wavelengths is measured, allowing determination of the absorbance. The color of the blood provides a measure of oxygenation (the percentage of hemoglobin molecules bound with oxygen molecules). A healthy young person will probably have an oxygen saturation of 95-99%.</description>
        <time_frame>60 minutes after drug administration</time_frame>
        <population>The analysis was done on the patients who completed the assessment. Three patients in the randomized midazolam arm and 3 patients in the placebo arm did not complete this assessment.</population>
        <group_list>
          <group group_id="O1">
            <title>Randomized Midazolam</title>
            <description>Randomized patients receiving single-dose midazolam syrup</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Randomized patients receiving placebo syrup</description>
          </group>
          <group group_id="O3">
            <title>Prospective Midazolam</title>
            <description>Open-label, dose of Midazolam based on patient's weight, additional doses to control anxiety were possible</description>
          </group>
        </group_list>
        <measure>
          <title>Pulse Oximetry at 60 Minutes</title>
          <description>Pulse oximetry measures the oxygenation of a patient's hemoglobin. A sensor is placed on the patients finger. Light at red and infrared wavelengths is passed sequentially through the patient to a photodetector. The changing absorbance at each of the two wavelengths is measured, allowing determination of the absorbance. The color of the blood provides a measure of oxygenation (the percentage of hemoglobin molecules bound with oxygen molecules). A healthy young person will probably have an oxygen saturation of 95-99%.</description>
          <population>The analysis was done on the patients who completed the assessment. Three patients in the randomized midazolam arm and 3 patients in the placebo arm did not complete this assessment.</population>
          <units>percentage of oxygenation</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="19"/>
                <count group_id="O2" value="19"/>
                <count group_id="O3" value="31"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="94.5" spread="2.43"/>
                    <measurement group_id="O2" value="96.4" spread="1.81"/>
                    <measurement group_id="O3" value="95.5" spread="3.03"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Patients were assessed for adverse events (AEs) during the 120 minutes after drug administration. Patients also were contacted by phone within 24 hours of the procedure using a specific inventory questionnaire to determine if there were any delayed AEs.</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Randomized Midazolam</title>
          <description>Randomized patients receiving single-dose midazolam syrup</description>
        </group>
        <group group_id="E2">
          <title>Placebo</title>
          <description>Randomized patients receiving placebo syrup</description>
        </group>
        <group group_id="E3">
          <title>Prospective Midazolam</title>
          <description>Open-label, dose of Midazolam based on patient's weight, additional doses to control anxiety were possible</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="31"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="31"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Mild and transient hypoxia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="31"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>The study was hindered by slow accrual and fell short of reaching the target number of patients.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Dr. Clark C. Otley</name_or_title>
      <organization>Mayo Clinic</organization>
      <phone>507-284-3579</phone>
      <email>otley.clark@mayo.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

